MX2022011593A - Formas cristalinas de un compuesto farmaceutico. - Google Patents

Formas cristalinas de un compuesto farmaceutico.

Info

Publication number
MX2022011593A
MX2022011593A MX2022011593A MX2022011593A MX2022011593A MX 2022011593 A MX2022011593 A MX 2022011593A MX 2022011593 A MX2022011593 A MX 2022011593A MX 2022011593 A MX2022011593 A MX 2022011593A MX 2022011593 A MX2022011593 A MX 2022011593A
Authority
MX
Mexico
Prior art keywords
crystalline forms
tyk2 inhibitor
tyk2
inhibitor
compound
Prior art date
Application number
MX2022011593A
Other languages
English (en)
Spanish (es)
Inventor
John Charles Reader
John Mykytiuk
Jamie Conor Marshall
Julian Scot Northen
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of MX2022011593A publication Critical patent/MX2022011593A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2022011593A 2020-04-07 2021-04-06 Formas cristalinas de un compuesto farmaceutico. MX2022011593A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2005114.0A GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound
PCT/EP2021/058864 WO2021204762A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor

Publications (1)

Publication Number Publication Date
MX2022011593A true MX2022011593A (es) 2022-10-18

Family

ID=70768933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011593A MX2022011593A (es) 2020-04-07 2021-04-06 Formas cristalinas de un compuesto farmaceutico.

Country Status (12)

Country Link
US (1) US12545652B2 (https=)
EP (1) EP4132649A1 (https=)
JP (1) JP7660135B2 (https=)
KR (1) KR20220164751A (https=)
CN (1) CN115515683B (https=)
AU (1) AU2021253128A1 (https=)
BR (1) BR112022016359A2 (https=)
CA (1) CA3167172A1 (https=)
GB (1) GB202005114D0 (https=)
IL (1) IL296989A (https=)
MX (1) MX2022011593A (https=)
WO (1) WO2021204762A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
WO2023183910A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Solid forms of tyk2 inhibitors and methods of use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
JPH0753716B2 (ja) 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
IL153246A0 (en) 2000-06-28 2003-07-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
DE60128731T2 (de) 2000-10-30 2008-02-07 Janssen Pharmaceutica N.V. Tripeptidylpeptidase-hemmer
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
JP5222561B2 (ja) 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
WO2008024980A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
JP5478488B2 (ja) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8420695B2 (en) 2008-07-09 2013-04-16 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN103987713A (zh) 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
EP3040336B1 (en) 2012-03-02 2020-04-08 Sareum Limited Compounds for use in treating tyk2 kinase mediated conditions
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
MX369974B (es) * 2013-09-03 2019-11-27 Sareum Ltd Compuestos farmaceuticos.
NO2721710T3 (https=) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB201816369D0 (en) * 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US20230159473A1 (en) 2023-05-25
BR112022016359A2 (pt) 2022-10-04
WO2021204762A1 (en) 2021-10-14
JP2023521631A (ja) 2023-05-25
US12545652B2 (en) 2026-02-10
CA3167172A1 (en) 2021-10-14
JP7660135B2 (ja) 2025-04-10
IL296989A (en) 2022-12-01
EP4132649A1 (en) 2023-02-15
CN115515683B (zh) 2024-10-25
KR20220164751A (ko) 2022-12-13
AU2021253128A1 (en) 2022-08-25
GB202005114D0 (en) 2020-05-20
CN115515683A (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
ZA202206923B (en) New methylquinazolinone derivatives
PH12022551503A1 (en) Kras mutant protein inhibitors
PH12021552048A1 (en) Jak inhibitor compound and use thereof
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MY209340A (en) Egfr inhibitor for the treatment of cancer
MX2023010411A (es) Inhibidores de erbb/btk.
MY210507A (en) New heterocyclic compounds as monoacylglycerol lipase inhibitors
MX2024005996A (es) Inhibidor de kif18a.
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
MX2022008487A (es) Degradadores de smarca2-vhl.
ZA202301937B (en) Compounds
MX2022016515A (es) Nuevo inhibidor de la secrecion de acido y uso del mismo.
MX2022010944A (es) Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
ZA202305622B (en) Free base crystalline form of a complement component c5a receptor
GEAP202215592A (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
MX2022006776A (es) Composiciones farmaceuticas oftalmicas.
MX2024015245A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2022011593A (es) Formas cristalinas de un compuesto farmaceutico.
GEAP202516246A (en) Magl inhibitor
MX2020008982A (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.
MX2024007457A (es) Formas cristalinas de n-(6-amino-5-metilpiridin-3-il)-2-(benzo[d]t iazol-5-il)-5- metilpiperidin-1-il)-2-oxoacetamida, composiciones farmacéuticas y métodos de uso de estas.
MX2020008230A (es) Derivados de ester butanoico sustituido con bisfenilo como inhibidores de nep.